v3.26.1
Business Segments - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Expenses [Abstract]        
Research and development $ 27,435 $ 34,449 $ 61,892 $ 70,187
Reportable Segment        
Segment Expenses [Abstract]        
Salaries and benefits and stock based compensation 10,681 12,034 25,440 24,757
Other research and development expense 4,659 5,987 10,285 11,440
Research and development 27,435 34,449 61,892 70,187
Reportable Segment | Zanidatamab        
Segment Expenses [Abstract]        
Research and development 2,181 1,501 2,805 2,905
Reportable Segment | ZW171        
Segment Expenses [Abstract]        
Research and development (458) 3,322 691 5,549
Reportable Segment | ZW191        
Segment Expenses [Abstract]        
Research and development 3,127 2,764 6,158 4,470
Reportable Segment | ZW220        
Segment Expenses [Abstract]        
Research and development (152) 327 (55) 2,525
Reportable Segment | ZW251        
Segment Expenses [Abstract]        
Research and development 3,205 2,340 5,112 6,291
Reportable Segment | Expense for other preclinical and research programs        
Segment Expenses [Abstract]        
Research and development $ 4,192 $ 6,174 $ 11,456 $ 12,250